<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29801" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sympathomimetics</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Horowitz</surname>
            <given-names>Alex J.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Frey</surname>
            <given-names>David</given-names>
          </name>
          <aff>Orlando Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Denault</surname>
            <given-names>Deanna</given-names>
          </name>
          <aff>MGH Institute of Health Professions</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Travis</given-names>
          </name>
          <aff>LECOM at Jacksonville University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alex Horowitz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Frey declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Deanna Denault declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Travis Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29801.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sympathomimetic drugs form a classification of medication used to manage and treat cardiovascular pathology, hypersensitivity, COPD, and glaucoma. This activity reviews the indications, action, and contraindications for sympathomimetics as valuable agents in treating and managing cardiovascular pathology (and other disorders when applicable). This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, monitoring, relevant interactions) pertinent for members of the healthcare team) in the management of patients with cardiovascular pathology and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of sympathomimetic drugs.</p></list-item><list-item><p>Describe the adverse effect profile of sympathomimetic drugs.</p></list-item><list-item><p>Review the appropriate monitoring needed for patients using sympathomimetic drugs.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to ensure the appropriate use of sympathomimetics and to reduce associated complications.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29801&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29801">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29801.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Sympathomimetic agents are used to augment the endogenous catecholamines of the sympathetic nervous system for therapeutic benefit. The body has a wide distribution of different adrenergic receptors across many organ systems. Without a thorough understanding of the adrenoreceptor subtypes involved in various tissues, the clinical effects observed can seem confusing due to overlapping receptor activities and different effects seen at different doses. Although beyond the scope of this review, the following is a summary with examples of currently FDA approved sympathomimetic indications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac: includes the treatment of hypotension, including those caused by hypovolemic, distributive, and neurogenic shock.<xref ref-type="bibr" rid="article-29801.r1">[1]</xref><xref ref-type="bibr" rid="article-29801.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Pulmonary: include the treatment of asthma and COPD.<xref ref-type="bibr" rid="article-29801.r3">[3]</xref><xref ref-type="bibr" rid="article-29801.r4">[4]</xref><xref ref-type="bibr" rid="article-29801.r5">[5]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sympathomimetic agents are used as nasal decongestants for the treatment of allergic rhinitis and conjunctivitis.<xref ref-type="bibr" rid="article-29801.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Ophthalmic indications: include open-angle glaucoma.<xref ref-type="bibr" rid="article-29801.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Neurologic: can even include local anesthetic effects.<xref ref-type="bibr" rid="article-29801.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Psychiatric: include the treatment of ADHD and narcolepsy.<xref ref-type="bibr" rid="article-29801.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Endocrine: include the treatment for obesity.<xref ref-type="bibr" rid="article-29801.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Genitourinary: include urinary incontinence.<xref ref-type="bibr" rid="article-29801.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>These indications are currently FDA approved; however, future applications for this versatile drug class are currently under investigation.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-29801.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Sympathomimetic agents may categorize as direct or indirect. Direct sympathomimetics function as agonists upon one or more adrenergic receptors. The pharmacological profile of direct sympathomimetics has its primary basis on the subtype of adrenergic receptors. Adrenergic receptor activity largely depends on the receptor's molecular structure, signaling pathway, anatomic distribution, and dosing concentration. Adrenergic receptors include the alpha and beta families. Direct sympathomimetics may act as selective or mixed agonists at the alpha and beta-adrenergic receptors. Alpha-adrenergic receptors subdivide into alpha-1 and alpha-2.<xref ref-type="bibr" rid="article-29801.r12">[12]</xref></p>
        <p>Beta-adrenergic receptors subdivide into beta-1, beta-2, and beta-3. Adrenergic receptors are G-protein-coupled metabotropic receptors that use guanosine triphosphate as a cofactor.<xref ref-type="bibr" rid="article-29801.r13">[13]</xref><xref ref-type="bibr" rid="article-29801.r14">[14]</xref> The exact nature of the coupled G-protein determines its identity and the corresponding effect of the downstream secondary signaling cascade, which is beyond the scope of this review. Indirect sympathomimetic agents achieve a similar effect via increasing the concentration of endogenous catecholamines within the synaptic cleft. This increase may occur via the displacement of stored norepinephrine or epinephrine from within presynaptic vesicles, reuptake inhibition, or inhibition of their metabolism by monoamine oxidase or catechol-o-methyltransferase.<xref ref-type="bibr" rid="article-29801.r15">[15]</xref></p>
      </sec>
      <sec id="article-29801.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Sympathomimetics administration may be via virtually any route available, including oral, rectal, topical, IO, IV, IM, intrauterine, endotracheal, and inhalation. The term sympathomimetic&#x000a0;forms a broad classification of medications, which is why a complete review of the wide variety of administration routes is beyond the scope of this article. Single sympathomimetic agent routes of administration may differ according to different desired pharmaceutical effects. Epinephrine administration &#x02013; IV, IM, IO, endotracheal &#x02013; is indicated emergently. Airway swelling requires inhaled epinephrine. Epinephrine and isoproterenol administration may be via the intramuscular route.<xref ref-type="bibr" rid="article-29801.r16">[16]</xref><xref ref-type="bibr" rid="article-29801.r17">[17]</xref> Dobutamine, norepinephrine, terbutaline, and ritodrine may be administered intravenously.<xref ref-type="bibr" rid="article-29801.r18">[18]</xref><xref ref-type="bibr" rid="article-29801.r19">[19]</xref><xref ref-type="bibr" rid="article-29801.r20">[20]</xref>&#x000a0;Midodrine, ritodrine, and clonidine may be administered orally.<xref ref-type="bibr" rid="article-29801.r21">[21]</xref><xref ref-type="bibr" rid="article-29801.r22">[22]</xref><xref ref-type="bibr" rid="article-29801.r23">[23]</xref>&#x000a0;</p>
        <p>Oral administration may be further subdivided based on temporal characteristics. Pseudoephedrine extended-release capsules are designed to release their medication gradually. After the capsule dissolves, the medication granules dissolve at different rates. Interference with the capsule may alter the rate of the capsule's dissolution, thus modifying the pharmacological onset, duration, and effect. For this reason, extended-release capsules should not be crushed or broken.<xref ref-type="bibr" rid="article-29801.r24">[24]</xref> Albuterol and salmeterol administration is via inhalation.<xref ref-type="bibr" rid="article-29801.r25">[25]</xref> Terbutaline may be administered subcutaneously, leading to local vasoconstriction.<xref ref-type="bibr" rid="article-29801.r26">[26]</xref> Brimonidine and pseudoephedrine may be administered topically.<xref ref-type="bibr" rid="article-29801.r27">[27]</xref><xref ref-type="bibr" rid="article-29801.r28">[28]</xref> Phenylephrine may also be administered rectally.<xref ref-type="bibr" rid="article-29801.r29">[29]</xref> There are cases reported with the epidural administration of phenylephrine or ephedrine for regional anesthesia.<xref ref-type="bibr" rid="article-29801.r30">[30]</xref></p>
      </sec>
      <sec id="article-29801.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>A thorough understanding of the pharmacological effect and the adrenergic receptor activity of sympathomimetic agents renders their adverse effects as the logical extension of excessive or unwanted adrenergic receptor activity, which can be fatal. Following a comprehensive literature review, the following is a brief survey of sympathomimetic agent adverse effects. Alpha-1 adrenergic receptor activity-predominant sympathomimetics such as phenylephrine or norepinephrine are associated with hypertension (with the possibility of hypertensive emergency), reflex bradycardia, piloerection, and urinary retention. Vasoconstriction may lead to ischemia and necrosis of the digits of the distal appendages.<xref ref-type="bibr" rid="article-29801.r31">[31]</xref><xref ref-type="bibr" rid="article-29801.r32">[32]</xref> Alpha-2 adrenergic receptor activity-predominant sympathomimetics such as clonidine are associated with sedation, respiratory depression, bradycardia and hypotension, miosis, rebound hypertension, and dry mouth.<xref ref-type="bibr" rid="article-29801.r33">[33]</xref></p>
        <p>Beta-1 adrenergic receptor activity-predominant sympathomimetics such as dobutamine are associated with tachycardia and arrhythmias. In patients with coronary artery disease, these adverse effects of beta-2 adrenergic receptor activity-predominant sympathomimetics may lead to acute coronary syndrome.<xref ref-type="bibr" rid="article-29801.r34">[34]</xref> Beta-2 adrenergic receptor activity-predominant sympathomimetics such as albuterol or salmeterol are most commonly associated with tremor.<xref ref-type="bibr" rid="article-29801.r35">[35]</xref> Additional adverse effects include agitation, insomnia, and diaphoresis. Beta-2-mediated coronary artery and skeletal muscle vasodilation may lead to hypotension and reflex tachycardia. Hyperinsulinemia, hyperglycemia, and hypokalemia are endocrine-associated adverse effects.<xref ref-type="bibr" rid="article-29801.r36">[36]</xref><xref ref-type="bibr" rid="article-29801.r37">[37]</xref></p>
        <p>Indirect sympathomimetics such as amphetamines, cocaine, or ephedrine are associated with anorexia, weight loss, insomnia, nausea, vomiting, abdominal cramps, mesenteric ischemia, motor tics, and seizures. Cardiovascular complications of indirect sympathomimetics similar to the direct agents may also include hypertension with reflex bradycardia, aortic dissection, tachycardia, myocardial infarction, and strokes.<xref ref-type="bibr" rid="article-29801.r9">[9]</xref><xref ref-type="bibr" rid="article-29801.r38">[38]</xref> Classically, beta-blockers must not be administered to patients misusing cocaine due to the risk of severe hypertension and end-organ damage resulting from the unopposed-alpha activity.<xref ref-type="bibr" rid="article-29801.r39">[39]</xref> Indirect sympathomimetic-associated rhabdomyolysis may lead to acute renal injury and, ultimately, multiple organ failure.<xref ref-type="bibr" rid="article-29801.r38">[38]</xref></p>
      </sec>
      <sec id="article-29801.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>No universal set of contraindications exists for all sympathomimetics, but a patient&#x02019;s current condition may offer relative contraindications and the need for careful titration or selection of a more appropriate sympathomimetic. Although extremely rare, true hypersensitivity reactions would be considered a contraindication to specific agents. Following a comprehensive literature review, the following is a brief survey of contraindications for major sympathomimetic agents. High doses of phenylephrine may also be associated with extreme reflex bradycardia or asystole. For this reason, phenylephrine is a relative contraindication in patients with a history of extreme bradycardia.<xref ref-type="bibr" rid="article-29801.r40">[40]</xref> Hypertrophic obstructive cardiomyopathy, also known as idiopathic hypertrophic subaortic stenosis, is a relative contraindication for dobutamine. Dobutamine administration in these patients may precipitate an episode of hypotension secondary to functional left ventricular outflow tract obstruction.<xref ref-type="bibr" rid="article-29801.r41">[41]</xref></p>
        <p>Heart failure or cardiac injury is a relative contraindication for isoproterenol. The administration of isoproterenol may exacerbate an episode of decompensated heart failure due to the inotropic effects that increase myocardial oxygen demand while simultaneously&#x000a0;decreasing myocardial oxygen supply.<xref ref-type="bibr" rid="article-29801.r42">[42]</xref> Asthma or hypersensitivity reactions are relative contraindications for cocaine, a local anesthetic, due to its tendency to precipitate allergic episodes.<xref ref-type="bibr" rid="article-29801.r43">[43]</xref><xref ref-type="bibr" rid="article-29801.r44">[44]</xref> Hypertension or cardiovascular disease such as arteriosclerosis is another contraindication for cocaine as well as amphetamine.<xref ref-type="bibr" rid="article-29801.r45">[45]</xref><xref ref-type="bibr" rid="article-29801.r46">[46]</xref><xref ref-type="bibr" rid="article-29801.r47">[47]</xref></p>
      </sec>
      <sec id="article-29801.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Sympathomimetic is a broad pharmacological classification. A wide variation in the therapeutic index exists among pharmacological agents in this class. Due to the high rates of complications, the supervision of a physician with extensive experience with sympathomimetics is the recommendation when administering catecholamines. More sensitive monitoring with intra-arterial blood pressures is necessary for the administration of high-dose catecholamines.<xref ref-type="bibr" rid="article-29801.r48">[48]</xref></p>
      </sec>
      <sec id="article-29801.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>No universal antidote or treatment exists for all sympathomimetic agents and is beyond the scope of this review. Although specific adrenergic antagonists may prove beneficial in certain adrenergic toxicities, frequently, withdrawal of the offending agent and supportive care is sufficient. When available, the correct balance of adrenergic antagonists may prove beneficial, but choosing the incorrect agents and/or dosing them incorrectly makes it possible to exacerbate toxic effects. The classic example of this is the use of beta-blockers in acute cocaine intoxication, potentially causing hypertensive crisis through unopposed alpha-1 vasoconstriction.<xref ref-type="bibr" rid="article-29801.r49">[49]</xref><xref ref-type="bibr" rid="article-29801.r50">[50]</xref></p>
        <p>Phentolamine, for another example, is an effective treatment for pheochromocytoma or norepinephrine overdose by antagonizing alpha-1 receptors.<xref ref-type="bibr" rid="article-29801.r51">[51]</xref> Metoprolol or esmolol intravenously are effective antidotes for dobutamine by blocking beta-1 receptors.<xref ref-type="bibr" rid="article-29801.r52">[52]</xref>&#x000a0;Nonselective beta receptor antagonists effectively treat refractory hypotension, dysrhythmias, or tachycardia in beta-2 adrenergic receptor predominant sympathomimetic agents such as albuterol.<xref ref-type="bibr" rid="article-29801.r53">[53]</xref> However, although direct antagonists exist, frequently supportive care is all that is required, and treatment involves a variety of medication classes: benzodiazepines for seizures or sedation, calcium channel blockers for blood pressure control, and/or heart rate control, nitroglycerin or nitroprusside for vasodilation are among available options.<xref ref-type="bibr" rid="article-29801.r36">[36]</xref></p>
      </sec>
      <sec id="article-29801.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sympathomimetic agents are useful in a wide variety of indications across numerous clinical settings. For this reason, many types of healthcare team members such as physicians, nurses, or pharmacists must be knowledgeable of the adverse effects, contraindications, and toxicity management. Patients must receive education from the team and be encouraged to immediately seek help if there is an overdose. [Level 5]</p>
        <p>Due to the&#x000a0;high rates of complications, the supervision of a physician with extensive experience with sympathomimetics is the recommended approach for administering catecholamines. The physician should also consult with a pharmacist to preclude any potential drug-drug interactions or additive effects with these medications; the pharmacist can recommend alternative agents or other modifications to the regimen to achieve therapeutic goals and minimize adverse effects. All healthcare team members should consult with a pharmacist regarding any concerns.<xref ref-type="bibr" rid="article-29801.r48">[48]</xref></p>
        <p>More sensitive monitoring with intra-arterial blood pressures is necessary for the administration of high-dose catecholamines. [Level 4] Nursing staff need to be well-versed in recognizing adverse events associated with sympathomimetic drugs. Since they will have more contact with the patient on an ongoing basis than other providers, the ability to monitor the patient effectively will fall under their duties. Nursing should be able to alert the doctor or contact the pharmacist with any questions or concerns.</p>
        <p>Best practice involves an interprofessional approach, with physicians, pharmacists, and nursing collaborating in a team effort to optimize patient care. [Level 5]</p>
      </sec>
      <sec id="article-29801.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29801&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29801">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29801/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29801">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29801.s11">
        <title>References</title>
        <ref id="article-29801.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Canepa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary and cardiac drugs: clinically relevant interactions.</article-title>
            <source>Herz</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>517</fpage>
            <page-range>517-521</page-range>
            <pub-id pub-id-type="pmid">31297545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>DeBlieux</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pressors and inotropes.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>823</fpage>
            <page-range>823-34</page-range>
            <pub-id pub-id-type="pmid">25441037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Jacques</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goldfrad</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: integrated analysis of four randomised trials.</article-title>
            <source>Respir Med</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>101</volume>
            <issue>11</issue>
            <fpage>2358</fpage>
            <page-range>2358-65</page-range>
            <pub-id pub-id-type="pmid">17689947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anzueto</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kostikas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mezzi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larbig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patalano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fogel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wedzicha</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.</article-title>
            <source>Respir Res</source>
            <year>2018</year>
            <month>Jun</month>
            <day>20</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>121</fpage>
            <pub-id pub-id-type="pmid">29925383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Marco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Santus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scichilone</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Solidoro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Contoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Braido</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corsico</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.</article-title>
            <source>Respir Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>125</volume>
            <fpage>49</fpage>
            <page-range>49-56</page-range>
            <pub-id pub-id-type="pmid">28340862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <article-title>OTC drugs for seasonal allergies.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2019</year>
            <month>Apr</month>
            <day>22</day>
            <volume>61</volume>
            <issue>1570</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">31169808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yokoyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maekawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Omodaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial.</article-title>
            <source>J Glaucoma</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>575</fpage>
            <page-range>575-583</page-range>
            <pub-id pub-id-type="pmid">31188229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aggarwal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Singla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miglani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kohli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the anaesthetic efficacy of epinephrine concentrations (1 : 80 000 and 1 : 200 000) in 2% lidocaine for inferior alveolar nerve block in patients with symptomatic irreversible pulpitis: a randomized, double-blind clinical trial.</article-title>
            <source>Int Endod J</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>373</fpage>
            <page-range>373-9</page-range>
            <pub-id pub-id-type="pmid">23895176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heal</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gosden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nutt</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Amphetamine, past and present--a pharmacological and clinical perspective.</article-title>
            <source>J Psychopharmacol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>479</fpage>
            <page-range>479-96</page-range>
            <pub-id pub-id-type="pmid">23539642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElroy</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic Treatments for Binge-Eating Disorder.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2017</year>
            <volume>78 Suppl 1</volume>
            <fpage>14</fpage>
            <page-range>14-19</page-range>
            <pub-id pub-id-type="pmid">28125174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsakiris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de la Rosette</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Oelke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence.</article-title>
            <source>Eur Urol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-9</page-range>
            <pub-id pub-id-type="pmid">17920183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Civantos Calzada</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aleixandre de Arti&#x000f1;ano</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Alpha-adrenoceptor subtypes.</article-title>
            <source>Pharmacol Res</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-208</page-range>
            <pub-id pub-id-type="pmid">11529686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>117</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-24; quiz 25</page-range>
            <pub-id pub-id-type="pmid">16387578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallukat</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The beta-adrenergic receptors.</article-title>
            <source>Herz</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>683</fpage>
            <page-range>683-90</page-range>
            <pub-id pub-id-type="pmid">12439640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators.</article-title>
            <source>J Neurochem</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-71</page-range>
            <pub-id pub-id-type="pmid">15228583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sicherer</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Simons</surname>
                <given-names>FER</given-names>
              </name>
              <collab>SECTION ON ALLERGY AND IMMUNOLOGY</collab>
            </person-group>
            <article-title>Epinephrine for First-aid Management of Anaphylaxis.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>139</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28193791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kimura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ushiyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mabuchi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[Diagnosis of angina pectoris by intravenous infusion of isoproterenol].</article-title>
            <source>Nihon Naika Gakkai Zasshi</source>
            <year>1968</year>
            <month>Jun</month>
            <day>10</day>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>644</fpage>
            <page-range>644-55</page-range>
            <pub-id pub-id-type="pmid">4972659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghimire</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dhungana</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of drugs used in chronic heart failure at tertiary care centre: a hospital based study.</article-title>
            <source>J Cardiovasc Thorac Res</source>
            <year>2019</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-84</page-range>
            <pub-id pub-id-type="pmid">31384400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grover</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma.</article-title>
            <source>Acta Paediatr</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>103</volume>
            <issue>12</issue>
            <fpage>1301</fpage>
            <page-range>1301-6</page-range>
            <pub-id pub-id-type="pmid">25164315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoneda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoneda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fukuta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shiozaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kigawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>In which preterm labor-patients is intravenous maintenance tocolysis effective?</article-title>
            <source>J Obstet Gynaecol Res</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>397</fpage>
            <page-range>397-407</page-range>
            <pub-id pub-id-type="pmid">29239057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anstey</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wibrow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thevathasan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chhangani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DiBiasio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eikermann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).</article-title>
            <source>BMC Anesthesiol</source>
            <year>2017</year>
            <month>Mar</month>
            <day>21</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <pub-id pub-id-type="pmid">28327122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yumoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sakata</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Preparation and evaluation of ritodrine buccal tablets for rational therapeutic use.</article-title>
            <source>Int J Pharm</source>
            <year>2014</year>
            <month>Jul</month>
            <day>01</day>
            <volume>468</volume>
            <issue>1-2</issue>
            <fpage>207</fpage>
            <page-range>207-13</page-range>
            <pub-id pub-id-type="pmid">24709218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasseur</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Houdas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harries</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Emul</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Systemic and Local Pharmacokinetics of Clonidine Mucoadhesive Buccal Tablets with Reference Clonidine Oral Tablets in Healthy Volunteers: An Open-Label Randomised Cross-Over Trial.</article-title>
            <source>Adv Ther</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>2022</fpage>
            <page-range>2022-2032</page-range>
            <pub-id pub-id-type="pmid">28726169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hashizume</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A novel approach to sustained pseudoephedrine release: differentially coated mini-tablets in HPMC capsules.</article-title>
            <source>Int J Pharm</source>
            <year>2008</year>
            <month>Jul</month>
            <day>09</day>
            <volume>359</volume>
            <issue>1-2</issue>
            <fpage>46</fpage>
            <page-range>46-52</page-range>
            <pub-id pub-id-type="pmid">18467046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Virk</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Hotz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khemani</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Newth</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers.</article-title>
            <source>Lung</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>195</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-239</page-range>
            <pub-id pub-id-type="pmid">28210808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hon</surname>
                <given-names>KLE</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>AKC</given-names>
              </name>
            </person-group>
            <article-title>Medications and Recent Patents for Status Asthmaticus in Children.</article-title>
            <source>Recent Pat Inflamm Allergy Drug Discov</source>
            <year>2017</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-21</page-range>
            <pub-id pub-id-type="pmid">28137226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Nadkarni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cardwell</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Alinia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability.</article-title>
            <source>Patient Prefer Adherence</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>1143</fpage>
            <page-range>1143-1150</page-range>
            <pub-id pub-id-type="pmid">28740369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erickson</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mingo</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Hey</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine.</article-title>
            <source>Am J Rhinol</source>
            <year>2001</year>
            <season>Mar-Apr</season>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-90</page-range>
            <pub-id pub-id-type="pmid">11345158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hern&#x000e1;ndez-Bernal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Castellanos-Sierra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Valenzuela-Silva</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Catas&#x000fa;s-&#x000c1;lvarez</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Valle-Cabrera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aguilera-Barreto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Saura</surname>
                <given-names>PA</given-names>
              </name>
              <collab>THERESA-3 Group of Investigators</collab>
            </person-group>
            <article-title>Recombinant streptokinase vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled trial (THERESA-3).</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Feb</month>
            <day>14</day>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>1594</fpage>
            <page-range>1594-601</page-range>
            <pub-id pub-id-type="pmid">24587636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martyr</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Orlikowski</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Epidural anaesthesia, ephedrine and phenylephrine in a patient taking moclobemide, a new monoamine oxidase inhibitor.</article-title>
            <source>Anaesthesia</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>12</issue>
            <fpage>1150</fpage>
            <page-range>1150-2</page-range>
            <pub-id pub-id-type="pmid">9038453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macmillan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Phenylephrine toxicity.</article-title>
            <source>Eur J Anaesthesiol</source>
            <year>2008</year>
            <month>May</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>426</fpage>
            <page-range>426-7</page-range>
            <pub-id pub-id-type="pmid">18377666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayd&#x00131;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tugcu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Toxicological assessment of epinephrine and norepinephrine by analog approach.</article-title>
            <source>Food Chem Toxicol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>118</volume>
            <fpage>726</fpage>
            <page-range>726-732</page-range>
            <pub-id pub-id-type="pmid">29913233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Manzon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nappe</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>DelMaestro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <chapter-title>Clonidine Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29083752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulman</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Cantral</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Meade</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Vettel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Loperena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Odrezin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dobutamine overdose.</article-title>
            <source>JAMA</source>
            <year>1990</year>
            <month>Nov</month>
            <day>14</day>
            <volume>264</volume>
            <issue>18</issue>
            <fpage>2386</fpage>
            <page-range>2386-7</page-range>
            <pub-id pub-id-type="pmid">2231992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;tvall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lunde</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Svedmyr</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients.</article-title>
            <source>Can Respir J</source>
            <year>1998</year>
            <season>May-Jun</season>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>191</fpage>
            <page-range>191-4</page-range>
            <pub-id pub-id-type="pmid">9707465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glatstein</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Rimon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marom</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scolnik</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Unintentional oral beta agonist overdose: case report and review of the literature.</article-title>
            <source>Am J Ther</source>
            <year>2013</year>
            <season>May-Jun</season>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-4</page-range>
            <pub-id pub-id-type="pmid">21317628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozdemir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Duman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Unal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tuncok</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia after albuterol overdose in a pediatric patient.</article-title>
            <source>Pediatr Emerg Care</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>464</fpage>
            <page-range>464-5</page-range>
            <pub-id pub-id-type="pmid">15232249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimmerman</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Cocaine intoxication.</article-title>
            <source>Crit Care Clin</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>517</fpage>
            <page-range>517-26</page-range>
            <pub-id pub-id-type="pmid">22998988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ramoska</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Fareed</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Izquierdo G&#x000f3;mez</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;-Blockers, Cocaine, and the Unopposed &#x003b1;-Stimulation Phenomenon.</article-title>
            <source>J Cardiovasc Pharmacol Ther</source>
            <year>2017</year>
            <month>May</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>239</fpage>
            <page-range>239-249</page-range>
            <pub-id pub-id-type="pmid">28399647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swenson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rankin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daconti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Villarreal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Langsjoen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Braude</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Safety of bolus-dose phenylephrine for hypotensive emergency department patients.</article-title>
            <source>Am J Emerg Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1802</fpage>
            <page-range>1802-1806</page-range>
            <pub-id pub-id-type="pmid">29472039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shao</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>WX</given-names>
              </name>
            </person-group>
            <article-title>[Comparison of dobutamine stress echocardiography and exercise echocardiography in evaluating left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy].</article-title>
            <source>Zhonghua Xin Xue Guan Bing Za Zhi</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>214</fpage>
            <page-range>214-8</page-range>
            <pub-id pub-id-type="pmid">22801266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>PQ</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>G3BP2 is involved in isoproterenol-induced cardiac hypertrophy through activating the NF-&#x003ba;B signaling pathway.</article-title>
            <source>Acta Pharmacol Sin</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>184</fpage>
            <page-range>184-194</page-range>
            <pub-id pub-id-type="pmid">28816235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armentia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Armentia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Armentia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruiz-Mu&#x000f1;oz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Quesada</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Postigo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Conde</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Sagrado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pineda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palacios</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tejedor</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cocaine Allergy in Drug-Dependent Patients and Allergic People.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>201</fpage>
            <page-range>201-207</page-range>
            <pub-id pub-id-type="pmid">28863944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Self</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>March</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Sands</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Asthma associated with the use of cocaine, heroin, and marijuana: A review of the evidence.</article-title>
            <source>J Asthma</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>714</fpage>
            <page-range>714-722</page-range>
            <pub-id pub-id-type="pmid">27858495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santurt&#x000fa;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Blanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fdez-Arroyabe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Santurt&#x000fa;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zarrabeitia</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Cocaine in Hospital Admissions for Diseases of the Circulatory System and as the Underlying Cause of Death: Analysis and Discussion.</article-title>
            <source>Cardiovasc Toxicol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-27</page-range>
            <pub-id pub-id-type="pmid">31273689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stankowski</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Kloner</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rezkalla</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular consequences of cocaine use.</article-title>
            <source>Trends Cardiovasc Med</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>517</fpage>
            <page-range>517-26</page-range>
            <pub-id pub-id-type="pmid">25657055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Havakuk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rezkalla</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kloner</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The Cardiovascular Effects of Cocaine.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>04</day>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-113</page-range>
            <pub-id pub-id-type="pmid">28662796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Medam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alingrin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haddam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hammad</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meyssignac</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vigne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zieleskiewicz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>NOREPINEPHRINE: NOT TOO MUCH, TOO LONG.</article-title>
            <source>Shock</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>305</fpage>
            <page-range>305-9</page-range>
            <pub-id pub-id-type="pmid">26125087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schurr</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Gitman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Belchikov</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Controversial therapeutics: the &#x003b2;-adrenergic antagonist and cocaine-associated cardiovascular complications dilemma.</article-title>
            <source>Pharmacotherapy</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>1269</fpage>
            <page-range>1269-81</page-range>
            <pub-id pub-id-type="pmid">25224512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fareed</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Death temporally related to the use of a Beta adrenergic receptor antagonist in cocaine associated myocardial infarction.</article-title>
            <source>J Med Toxicol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>169</fpage>
            <page-range>169-72</page-range>
            <pub-id pub-id-type="pmid">18072171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>von K&#x000e4;nel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heimgartner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zuccarella-Hackl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000fc;rkle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ehlert</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>The Role of Norepinephrine and &#x003b1;-Adrenergic Receptors in Acute Stress-Induced Changes in Granulocytes and Monocytes.</article-title>
            <source>Psychosom Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>80</volume>
            <issue>7</issue>
            <fpage>649</fpage>
            <page-range>649-658</page-range>
            <pub-id pub-id-type="pmid">29965944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murthy</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Katten</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ahlberg</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Salloum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.</article-title>
            <source>Pharmacotherapy</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>1303</fpage>
            <page-range>1303-9</page-range>
            <pub-id pub-id-type="pmid">11079278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29801.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramoska</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Henretig</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Joffe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Propranolol treatment of albuterol poisoning in two asthmatic patients.</article-title>
            <source>Ann Emerg Med</source>
            <year>1993</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>1474</fpage>
            <page-range>1474-6</page-range>
            <pub-id pub-id-type="pmid">8363123</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
